IPO

Insys Therapeutics, which markets an opioid and synthetic marijuana drug for cancer pain and CINV, raised $32 million by offering 4 million shares at $8, at low end of the range of $8 to $10. The company had previously filed to offer 4 million shares at a range of $16 to $18. Insys Therapeutics will list on the NASDAQ under the symbol INSY. Wells Fargo Securities and JMP Securities acted as lead managers on the deal

SUBSYS SPRAY

Subsys ® is a proprietary, single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue.

Drug	Indication	Preclinical	Phase 1	Phase 2/3	NDA	Approved
Subsys® Spray (NDA)	BTCP in Opioid Tolerant Patients
Dronabinol Oral Solution (Phase 3)	CINV
Dronabinol Generics
Liposomal Encapsulated Paclitaxel (Phase 2)	Metastic Cancers

We are assembling a product pipeline targeting cancer-supportive care and cancer therapy that we believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization.

Drug	Indication	Preclinical	Phase 1	Phase 2/3	NDA	Approved
Fentanyl Sublingual Spray	BTCP in Opioid Tolerant Patients
Dronabinol Oral Solution (Pre-NDA)	CINV